reports
- ING Helpdesk
Benelux Morning Notes
CFE: Preview: underlying 2026 margin to improve / DEME: Preview: strong 2025, eyes on 2026 outlook / JDE Peet's: Acquisition by KDP expected to close in 2Q26 / Solvay: 2025 ends with strong FCF; 2026F und. EBITDA guidance slightly below, supported by one-off / UCB: Peer Moonlake investor day / Vastned: Beat on bottom line with operational metrics accelerating, but outlook remains weak
- Maxime Stranart
- Reg Watson
- CFA
Ontex/Another challenging year ahead/HOLD
We reiterate our HOLD rating on Ontex and lower our target price from €5.40 to €4.70, following the group's weaker-than-expected FY25 results and a FY26 guidance we see as challenging, especially given the strong headwinds the company will have to cope with over 1H26. Ontex's material exposure to the Baby care segment remains the most challenged one in our view, given unsupportive demographics trends in key markets and material price and promotion pressure from branded players. At €4.7, Ontex wo...
IBA – ACQUISITION OF OWN SHARES
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 23rd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 20...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 23 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à part...
ARGAN: INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHA...
ARGAN: INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPOSING THE SHARE CAPITAL ON FEBRUARY 18, 2026 Press release – Neuilly-sur-Seine, Monday, February 23, 2026 – 5.45pm Information regarding the total number of voting rights and shares composing the share capital on February 18, 2026 On February 18, 2026, the day we released our notice of meeting ahead of our Combined General Meeting of Shareholders – to be held on March 26, 2026 – the total number of voting rights and shares composing ARGAN’s share capital was as follows: February 18, 2026Total number of shares i...
ARGAN : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’...
ARGAN : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL À LA DATE DU 18 FÉVRIER 2026 Communiqué de presse – Neuilly-sur-Seine, lundi 23 février 2026 - 17h45 Informations relatives au nombre total de droits de vote et d’actions composant le capital à la date du 18 février 2026 Au 18 février 2026, date de publication de l’avis de réunion préalable à l’Assemblée Générale Mixte devant se tenir le 26 mars 2026, le nombre total de droits de vote et d’actions composant le capital d’ARGAN est le suivant : 18 février 2026Nombre total d'actions composant ...
Zealand Pharma convenes its Annual General Meeting 2026
Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...
- Charlotte Vaisse
- Equipe Sustainability
- Julian Dobrovolschi
- Marc Lavaud
ENX EURONEXT NV
PEO BANK POLSKA KASA OPIEKI SA
CA CARREFOUR SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
EFGN EFG INTERNATIONAL AG
COV COVIVIO SA
ORA ORANGE SA
TKA TELEKOM AUSTRIA AG
RI PERNOD RICARD SA
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
AIR AIRBUS SE
VER VERBUND AG CLASS A
REP REPSOL SA
BA. BAE SYSTEMS PLC
CRG CRH PLC
GAS NATURGY ENERGY GROUP S.A.
ACKB ACKERMANS & VAN HAAREN NV
ARCAD ARCADIS NV
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
SAN BANCO SANTANDER S.A.
RIO RIO TINTO PLC
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
KBX KNORR-BREMSE AG
MRNA MODERNA INC.
FDJ LA FRANCAISE DES JEUX SA
FER FERROVIAL SA
AGN AEGON N.V.
TEN TENARIS S.A.
PUIG PUIG BRANDS
AMRZ AMRIZE AG
EcoVadis Gold rating validates Ontex’s business sustainability commitm...
EcoVadis Gold rating validates Ontex’s business sustainability commitments and performance for second year in a row Aalst, Belgium, February 19, 2026 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, announces that it has been awarded a Gold rating by EcoVadis for the second consecutive year. EcoVadis, a global leader in business sustainability assessments, awarded Ontex a higher total score year on year, placing the company in the top 3% of companies assessed globally. The recognition reflects the solid foundations Ontex has bu...
EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamhe...
EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamheidsengagement en -prestaties van Ontex Aalst, België, 19 februari 2026 – Ontex Group NV [EURONEXT: ONTEX], een toonaangevende ontwikkelaar en producent van persoonlijke verzorgingsproducten, heeft het tweede jaar op rij een gouden medaille van EcoVadis ontvangen. EcoVadis, wereldwijd toonaangevend in duurzaamheidsbeoordelingen van bedrijven, kende Ontex een hogere totaalscore toe dan vorig jaar. Ontex behoort daarmee vandaag tot de top 3% van de wereldwijd beoordeelde bedrijven. De erkenning weerspiegelt de solide funda...
- Charlotte Vaisse
- Equipe Sustainability
- Julian Dobrovolschi
- Marc Lavaud
ENX EURONEXT NV
PEO BANK POLSKA KASA OPIEKI SA
CA CARREFOUR SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
EFGN EFG INTERNATIONAL AG
COV COVIVIO SA
ORA ORANGE SA
TKA TELEKOM AUSTRIA AG
RI PERNOD RICARD SA
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
AIR AIRBUS SE
VER VERBUND AG CLASS A
REP REPSOL SA
BA. BAE SYSTEMS PLC
CRG CRH PLC
GAS NATURGY ENERGY GROUP S.A.
ACKB ACKERMANS & VAN HAAREN NV
ARCAD ARCADIS NV
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
SAN BANCO SANTANDER S.A.
RIO RIO TINTO PLC
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
KBX KNORR-BREMSE AG
MRNA MODERNA INC.
FDJ LA FRANCAISE DES JEUX SA
FER FERROVIAL SA
AGN AEGON N.V.
TEN TENARIS S.A.
PUIG PUIG BRANDS
AMRZ AMRIZE AG
- Mathijs Geerts Danau
Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...
Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expan...
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...
Zealand Pharma Announces Financial Results for the Full Year 2025
Zealand Pharma Announces Financial Results for the Full Year 2025 Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading...
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre...
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...
- Thijs Berkelder
ARGAN signe un nouveau bail de 10 000 m² sur son entrepôt AutOnom® d’A...
ARGAN signe un nouveau bail de 10 000 m² sur son entrepôt AutOnom® d’Augny (57) Communiqué de presse – Neuilly-sur-Seine, mercredi 18 février 2026 - 17h45 ARGAN signe un nouveau bail de 10 000 m² sur son entrepôt AutOnom® d’Augny (57) ARGAN annonce la relocation de son site logistique AutOnom® situé à Augny (57), dans la région de Metz, à la société MPM Group, acteur de référence dans le domaine des solutions professionnelles de sonorisation, d’éclairage, de vidéo et de structures scéniques. Implanté sur le plateau de Frescaty, à Augny (57), face à l’entrepôt ARGAN loué à AMAZON de 185 0...
ARGAN signed a new 10,000 sq.m lease for its AutOnom® warehouse in Aug...
ARGAN signed a new 10,000 sq.m lease for its AutOnom® warehouse in Augny (57) Press release – Neuilly-sur-Seine, Wednesday, February 18, 2026 – 5.45 pm ARGAN signed a new 10,000 sq.m lease for its AutOnom® warehouse in Augny (57) ARGAN announced the re-letting of its AutOnom® logistics site located in Augny (57), in the Metz area, to MPM Group, a leading company in professional sound, lighting, video, and stage structure solutions. Located on the Frescaty plateau in Augny (57), opposite the 185,000 sq.m ARGAN warehouse leased to AMAZON, this latest-generation logistics platform offers ap...
- Mathijs Geerts Danau
Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker
Zealand Pharma reported positive phase 1a topline results for the Kv1.3 channel blocker ZP9830. Single ascending doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings, and PK/PD profile was in-line with predictions. We view these data as de-risking for the program and look forward to the MAD data expected in 2H26, which should provide insight into extended exposure and additional proof of mechanism. Given the selective expression of Kv1.3 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.